Heat Biologics is a biopharmaceutical company developing immunotherapies designed to activate a patient's immune system against cancer by harnessing the power of CD8+ "Killer" T-cells, the immune cells crucial in tumor cell killing. Heat’s T-Cell Activation Platform ("TCAP") is designed to turn "cold" tumors "hot" and is administered in combination with checkpoint therapies and other immuno-modulators to increase their effectiveness. HS-110 (ImPACT) is the company’s first biologic product candidate in a series of proprietary immunotherapies designed to stimulate a patient's own T-cells to attack cancer. Heat’s ComPACT technology is the first potential, dual-acting immunotherapy designed to deliver T-cell activation and co-stimulation in a single product. Currently, patient enrollment is ongoing in a Phase 2 clinical trial with HS-110 for advanced non-small cell lung cancer, in combination with Bristol-Myers Squibb's nivolumab (Opdivo®) and with Merck's pembrolizumab (Keytruda®). Pelican Therapeutics, a subsidiary of Heat, is focused on the development of co-stimulatory monoclonal antibody and fusion protein-based therapies designed to activate the immune system. Heat’s pipeline also includes numerous pre-clinical programs at various stages of development.
From the publishers of Nature, the BioPharma Dealmakers website brings together life sciences companies and individuals looking to identify and attract partners and dealmaking opportunities. It provides insights into dealmaking trends from BioPharma Dealmakers Editors, profiles from companies looking to partner, tools for networking and sharing knowledge, and the opportunity for sponsoring companies to showcase their expertise. BioPharma Dealmakers is THE destination for partnering professionals looking to make connections and get the latest on their industry.